Tempus AI TEM is leaning into a dual-engine model: a fast-growing Genomics franchise and a scaling data business powered by an expanding AI toolkit. The third quarter of 2025 marked a turn to non-GAAP ...

Tempus AI TEM is developing and deploying a suite of advanced algorithms and diagnostic software that run on its multimodal data. These algorithms span beyond oncology, including digital pathology, ...

Tempus’s strategy begins with what is the diagnostic that's going to be most commonly ordered in this disease area and how ...

Tempus AI hits multi-year lows despite 500+ PB proprietary healthcare data and precision medicine AI. Click here to read more ...

Artificial intelligence (AI) has been a huge investing theme over the past couple of years. Chances are, if you invested in a company involved with AI, you've seen its shares take off at some point.

Median Technologies has forged a partnership with Tempus AI, setting the former company up with its first US distribution agreement for eyonis lung cancer screening (LCS) since the software’s US Food ...

Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 2:00 PM EDTCompany ParticipantsEric Lefkofsky - ...

Market snapshot and recent moves Tempus AI (TEM) has drawn fresh attention after a strong single-day move, with the stock up about 10% on the latest close at US$52.26, compared with weaker returns ...